P27 Inhibitors for Hearing Regeneration and/or Breast Cancer (SJ-18-0016)

St. Jude Reference #SJ-18-0016

Description

Researchers at St. Jude have identified compounds that target intrinsically disordered proteins (IDPs). They inhibit disordered proteins by sequestration them in soluble oligomers. Inhibition of a specific IDP, p27Kip1 (p27 hereafter), was demonstrated and may represent a general mechanism for inhibition of IDPs associated with human disease.

Small molecules were identified that bind to p27 and cause it to be sequestered within soluble oligomers, altering its cell cycle regulatory function. Potential applications include inhibiting the function of p27 in the cells of the inner ear of hearing damaged individuals with the potential to enable hearing cell regeneration; and/or inhibiting interactions between p27 and RhoA in certain breast cancers.


 

Keywords

Intrinsically disordered protein (IDP), p27Kip1, p27, small molecules, compounds, soluble oligomers, inner ear, hearing damage, hearing cell regeneration, breast cancers.Intrinsically disordered protein (IDP), p27Kip1, p27, small molecules, compounds, soluble oligomers, inner ear, hearing damage, hearing cell regeneration, breast cancers.


 

Granted Patents or Published Applications


 

Related Scientific References


 

Licensing Opportunities

More information is available under a confidentiality agreement. Contact: chad.riggs@stjude.org

Related Links

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

For updates on COVID-19, please read.